Join the Oncology Voice Network. Join for Free
KEYS to SUCCESS in small start-ups vs. big pharma
Small Pharma Companies Transitioning to Smaller Firms Field Medical Roles Recruitment Challenges Career Progression in Biotech

KEYS to SUCCESS in small start-ups vs. big pharma


Share This Article


Summary

In this episode, Tom Caravela is joined by Jim Morgan to explore the unique landscape of working in small pharma companies. Jim shares insights from his extensive background in large pharma, highlighting the pros and challenges of transitioning to smaller firms. They discuss the critical role of field medical in companies lacking commercial teams and the recruitment challenges faced by small pharma. The conversation delves into strategic and tactical roles, team dynamics, and career progression within small biotech environments. Jim offers valuable advice for those considering a move to small pharma startups, emphasizing job stability and growth opportunities.

Jim Morgan, National Director, Oncology MSLs, discusses the KEY to success for working in small start ups vs. big pharma.

Jim shares…

👉 Pros and cons for Small vs. Large Pharma

👉 How to overcome lack of infrastructure and support

👉 What its like to navigate in an early stage, pre-commercial environment

👉 How to be both strategic and tactical at the same time

👉 What skills are mandatory for Small Pharma vs Large

Click for Source
Small Pharma Companies, Transitioning to Smaller Firms, Field Medical Roles, Recruitment Challenges, Career Progression in Biotech

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN